Evidence map›Paper›PMID 35741651›Full record

ArticleBrain sciences2022

Deep Brain Stimulation in Early-Stage Parkinson's Disease: Patient Experience after 11 Years.

Kaitlyn Stoehr, Kian Pazira, Kemberlee Bonnet, David Schlundt, David Charles, Mallory Hacker

Open access · goldAbstract read
In one paragraph

Article in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Eleven-Year Outcomes of Deep Brain Stimulation in Early-Stage Parkinson Disease.Neuromodulation : journal of the International Neuromodulation Society · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kaitlyn StoehrDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Kian PaziraDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Kemberlee BonnetDepartment of Psychology, Vanderbilt University, Nashville, TN 37235, USA.
David SchlundtDepartment of Psychology, Vanderbilt University, Nashville, TN 37235, USA.
David CharlesDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Mallory HackerDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0003-1498-4509
Vanderbilt University Medical Center · USVanderbilt University · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Feasibility of Objective Measures and Outpatient Washout in Disease-Modifying Trials for Parkinson's DiseaseK01AG066971 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HACKER, MALLORY L. · 2021 to 2025
$596k
Investigating Long-Term Clinical Outcomes and Metabolic Network Activity Following Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson's DiseaseR21NS107877 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HACKER, MALLORY L. · 2018 to 2019
$425k
American Parkinson Disease Association ResearchGrantNCATS NIH HHS UL1 TR002243NIA NIH HHS K01 AG066971NINDS NIH HHS R21 NS107877NINDS NIH HHS R21NS107877
6 · The paper itself

Abstract

The deep brain stimulation (DBS) in early-stage Parkinson's disease (PD) pilot trial began more than a decade ago and remains the only investigation of DBS in mildly symptomatic patients. Patients completed therapeutic washouts biannually for two years, outpatient assessments through five years, and a longitudinal washout assessment after 11 years. Here, the patient experience of participating in the early DBS pilot trial is described. Semi-structured interviews were audio-recorded and transcribed. Transcripts were coded, analyzed using an iterative inductive-deductive approach, and used to develop a conceptual framework. Ten participants (n = 6 early optimal drug therapy (ODT), n = 4 early DBS + ODT) were interviewed. Motivations for participation included benefit to future PD patients and potential personal benefit, while hesitations included risk of surgical complications. While early ODT patients who received standard-of-care DBS described significant changes in their functional capacities after surgery, early DBS patients described a maintenance of quality of life that made PD less impactful over an extended period. Patients expressed high satisfaction with trial participation and early DBS. This study suggests that the PD experience with early DBS may notably differ from standard-of-care DBS. The FDA has approved the conduct of a pivotal clinical trial evaluating DBS in early-stage PD (IDEG050016).

Indexed as

clinical trialsdeep brain stimulationParkinson’s diseasepatient experiencequalitative research

Identifiers

PMID35741651
PMCPMC9220916
OpenAlexW4282947135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.